Moderate riskFDA DeviceClass II

Siemens Atellica CH A1c test recalled for possible bias in results

Siemens Healthcare Diagnostics is recalling all lots of the Atellica CH Enzymatic Hemoglobin A1c (A1c_E) assay. The notice says there is a potential for intermittent well-to-well bias on Atellica CH and Atellica CI analyzers, which could cause falsely depressed or falsely elevated HbA1c patient results. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Siemens recalls

What to do

  1. Stop using the affected A1c_E assay, material number 11097536, on all lots.
  2. Identify affected product by material number 11097536 and UDI-DI 00630414220505. All lot numbers are included.
  3. Contact Siemens Healthcare Diagnostics for next steps. The notice doesn't specify a remedy, such as a replacement or correction.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
24,077 units
Illnesses reported
None reported
Manufactured in
511 Benedict Ave, N/A, Tarrytown, NY, United States
Classification
Class II
Recall number
Z-2703-2026

In the FDA's words

Description
Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536. The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results. Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers. Distribution: Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Oman, Pakistan, Paraguay, Poland, Portugal, Qatar, Republic of Korea, Romania, Saudi¿Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, Turkey, Turkmenistan, U.A.E., Uganda, United¿Kingdom, Uruguay, Vatican City, Vietnam. Affected quantity: 24,077 units
Hazard
The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.

More from Siemens

See all

Related topics